Paliperidone
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Paliperidone: From Schizophrenia to Retinal Dystrophy (Top TxGNN Prediction)
One-Sentence Summary
Paliperidone is an antipsychotic originally used to treat schizophrenia and related psychotic disorders. The TxGNN model's top-ranked prediction is retinal dystrophy with or without extraocular anomalies, but no clinical trials and no publications support it; it is a purely computational output. The only prediction with any supporting studies is treatment-refractory schizophrenia (3 clinical trials, 2 reviews), and that is a subpopulation of the already approved use rather than a true new indication.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Schizophrenia, schizoaffective disorder, schizophreniform disorder, psychotic disorder (from the knowledge graph; no approved indication text is recorded in the Singapore licence data) |
| Predicted New Indication | Retinal dystrophy with or without extraocular anomalies |
| TxGNN Prediction Score | 99.92% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 17 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Paliperidone is known to be a dopamine D2 and serotonin 5-HT2A receptor antagonist, and its efficacy in schizophrenia is established.
For the top prediction, retinal dystrophy, no plausible mechanistic link is supported. Inherited retinal dystrophies are genetic degenerative conditions, and there is no evidence that D2/5-HT2A antagonism alters their course. The high score (0.999) reflects a model output only; it should not be read as evidence of efficacy.
The same applies to the other top-ranked predictions: several forms of myopia (X-linked, syndromic, female-limited), hydranencephaly, a congenital disorder of glycosylation, perisylvian polymicrogyria, Charcot-Marie-Tooth disease type 1G and atypical glycine encephalopathy. All have no trials or literature, and mostly involve structural, metabolic or genetic defects that a symptomatic antipsychotic is unlikely to modify. A speculative link between retinal dopamine signalling and myopia has been suggested, but it is unsupported here.
The one prediction with a coherent rationale is treatment-refractory schizophrenia (rank 10, score 99.80%). Paliperidone's mechanism clearly fits, but this is a subgroup of its approved indication, and clozapine remains the evidence-based standard for refractory disease.
Clinical Trial Evidence
No clinical trials are registered for the top predicted indication (retinal dystrophy). Currently no related clinical trials registered.
For reference, the trials found for the only evidence-supported prediction, treatment-refractory schizophrenia:
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT06060886 | Phase 4 | Unknown | 244 | Randomised open-label comparison of aripiprazole vs paliperidone/risperidone using multi-omics data in first-episode psychosis (relevance grade B) |
| NCT07047651 | Phase 4 | Active, not recruiting | 84 | Pharmacotherapy combined with recovery-oriented programmes in treatment-resistant schizophrenia and bipolar disorder; no paliperidone-specific signal |
| NCT05741502 | Phase 4 | Terminated | 5 | Exploratory immune/inflammatory comparison of clozapine vs non-clozapine antipsychotics; negligible evidence given 5 participants |
Literature Evidence
No literature is available for the top predicted indication (retinal dystrophy). Currently no related literature available.
For reference, literature found for treatment-refractory schizophrenia:
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 31648341 | 2019 | Review | Actas Esp Psiquiatr | Psychopharmacology of schizoaffective disorder; treatment relies mainly on antipsychotics, with few condition-specific studies |
| 23364281 | 2013 | Review | Curr Opin Psychiatry | Efficacy and tolerability of psychosocial and drug treatments in early-onset schizophrenia spectrum disorders, with dosing, switching and adverse-effect guidance |
Singapore Market Information
Paliperidone has 17 valid single-ingredient registrations. The approved indication text is not recorded in the licence data. Five representative authorisations:
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN13380P | Invega Extended-Release Tablet 3mg | Extended-release tablet | Not recorded |
| SIN13969P | INVEGA Sustenna 50mg/0.5 ml | Extended-release IM injectable suspension | Not recorded |
| SIN15186P | INVEGA TRINZA 175mg/0.875ml | Extended-release IM injectable suspension | Not recorded |
| SIN16655P | INVEGA HAFYERA 1000mg/5ml | Extended-release IM injectable suspension | Not recorded |
| SIN16781P | PARNIDO Prolonged-Release Tablets 3mg | Multilayer extended-release tablet | Not recorded |
The remaining registrations cover other strengths of the same products (Invega tablets, Sustenna, Trinza, Hafyera and Parnido).
Safety Considerations
Package insert warnings and contraindications were not available for this report. Please refer to the package insert for safety information.
Supplementary information from the knowledge graph (not label text):
- Contraindication-related conditions: The knowledge graph links paliperidone to many conditions, including long QT syndrome, torsades de pointes, orthostatic hypotension, epilepsy, diabetes mellitus and diabetic ketoacidosis, hyperglycaemia, neutropenia and agranulocytosis, myocardial infarction, impaired renal function, hyperlipidaemia, obesity, Crohn disease and inflammatory bowel disease, and basal ganglia disease.
- Drug interactions: 100 interactions were found in total. Major interactions include bupropion and morphine. Moderate interactions include antidiabetic agents (acarbose, metformin, pioglitazone, canagliflozin, chlorpropamide, alogliptin, albiglutide), anticholinergics (atropine, hyoscyamine, glycopyrronium), epinephrine, hydrocortisone, famotidine, loperamide, bisacodyl, amphotericin B and lorcaserin.
For retinal dystrophy and the myopia predictions, which would often involve paediatric or syndromic patients, long-term systemic antipsychotic exposure would raise significant safety concerns (metabolic, cardiac and neurological effects).
Conclusion and Next Steps
Decision: Hold
Rationale: The top prediction (retinal dystrophy) rests on a model score alone, with no trials, no literature and no plausible mechanism, so it is Evidence Level L5. The only prediction with supporting studies, treatment-refractory schizophrenia, is a subgroup of the existing indication and not a true repurposing; the supplied trials show no paliperidone-specific efficacy.
To proceed, the following is needed:
- Mechanism of action data and a testable biological hypothesis linking paliperidone to retinal or ocular pathology
- Preclinical evidence (cell or animal models) for the top-ranked predictions
- Package insert warnings and contraindications for a safety screen
- For treatment-refractory schizophrenia: head-to-head evidence against clozapine and other standards, if pursued as a research question
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.